
Opinion|Videos|March 4, 2025
Treatment Options in mCRC: A Clinical Overview
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Advertisement
Video content above is prompted by the following:
- Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
- Fruquintinib
- Regorafenib
- Trifluridine + tipiracil ± bevacizumab
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5